News and Trends 30 Jan 2017
The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy
UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy for hemophilia B. UniQure is one of the companies leading the development of gene therapy for hemophilia. Now, the FDA has granted Breakthrough Therapy Designation to its candidate AMT-060 for hemophilia B. This is awarded to selected therapies that have […]
